Biosimilar Development News

  1. Interchangeable Biosimilars Market Revenue To Hit USD 65 Billion By 2035, Says Research Nester 9/11/2023

    The global Interchangeable Biosimilars market size is slated to expand at ~ 20 % CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 65 Billion by the end of 2035, up from a revenue of ~USD 25 Billion in the year 2022.

  2. Samsung Bioepis Partners With Sandoz To Commercialize Ustekinumab Biosimilar Candidate 9/11/2023

    Samsung Bioepis Co., Ltd. today announced that it has entered into a commercialization agreement with Sandoz for SB17, a proposed biosimilar to Stelarai (ustekinumab), marking a step forward in strengthening access to Samsung Bioepis’ immunology portfolio in the United States (US), Canada, European Economic Area (EEA), Switzerland and United Kingdom (UK).

  3. Sandoz Announces Exclusive Deal To Commercialize Biosimilar ustekinumab, Further Reinforcing Growing Pipeline And Immunology Patient Offering 9/11/2023

    Sandoz, a global leader in generic and biosimilar medicines, today announced that it has entered into a development and commercialization agreement with Samsung Bioepis.

  4. Celltrion Celebrates A Decade Of Biosimilar Innovation In Europe 9/10/2023

    Celltrion Healthcare today launches a campaign to celebrate a decade of continuous biosimilar innovation in Europe. The campaign coincides with 10 years since the world’s first monoclonal antibody biosimilar infliximab, Remsima, received regulatory approval from the European Medicines Agency (EMA).

  5. Dxcover Announces Expansion Of Its Leadership Team To Support Advancement Of Its Multi-Cancer Liquid Biopsy Platform 9/6/2023

    Dxcover Limited, a clinical-stage diagnostics company pioneering Multi-Omic Spectral Analysis for early detection of multiple cancers, today announced it has named Ron Andrews as its Non-Executive Chair.

  6. Remicade Biosimilar Market Size, Share, Revenue, Trends And Drivers For 2023-2032 9/6/2023

    The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

  7. Biocon Biologics Continues To Expand Global Footprint, Completes Integration Of Viatris Biosimilars' Business In North America Ahead Of Schedule 9/6/2023

    Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the Company has completed the integration of the acquired biosimilars business from Viatris in North America (United States and Canada) effective September 1, 2023.

  8. Alvotech Announces Changes To The Leadership Team 9/5/2023

    Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that Faysal Kalmoua has been appointed Alvotech’s Chief Operating Officer and Hafrun Fridriksdottir is stepping down following resubmission of the Biologics License Application (BLA) for AVT02, Alvotech’s proposed high-concentration interchangeable biosimilar to Humira® (adalimumab).

  9. Humira Biosimilar To See $832M In Sales By 2029, Forecasts Globaldata 9/1/2023

    Samsung Bioepis and Organon recently announced positive topline results from a Phase IV clinical trial of SB5, a biosimilar to the reference tumor necrosis factor (TNF) blocker Humira (adalimumab), in patients with moderate-to-severe chronic plaque psoriasis (PsO).

  10. US Capital Global Engaged By PlantForm Corporation As Strategic Advisor On $25M Capital Formation 8/31/2023

    US Capital Global has been engaged by PlantForm Corporation (“PlantForm” or the “Company”) as its strategic financial advisor on a $25 million debt and equity financing.